1045858-10-3Relevant articles and documents
Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections
Magee, Thomas V.,Ripp, Sharon L.,Li, Bryan,Buzon, Richard A.,Chupak, Lou,Dougherty, Thomas J.,Finegan, Steven M.,Girard, Dennis,Hagen, Anne E.,Falcone, Michael J.,Farley, Kathleen A.,Granskog, Karl,Hardink, Joel R.,Huband, Michael D.,Kamicker, Barbara J.,Kaneko, Takushi,Knickerbocker, Michael J.,Liras, Jennifer L.,Marra, Andrea,Medina, Ivy,Nguyen, Thuy-Trinh,Noe, Mark C.,Obach, R. Scott,O'Donnell, John P.,Penzien, Joseph B.,Reilly, Usa Datta,Schafer, John R.,Shen, Yue,Stone, Gregory G.,Strelevitz, Timothy J.,Sun, Jianmin,Tait-Kamradt, Amelia,Vaz, Alfin D. N.,Whipple, David A.,Widlicka, Daniel W.,Wishka, Donn G.,Wolkowski, Joanna P.,Flanagan, Mark E.
, p. 7446 - 7457 (2009)
Respiratory tract bacterial strains are becoming increasingly resistant to currently marketed macrolide antibiotics. The current alternative telithromycin (1) from the newer ketolide class of macrolides addresses resistance but is hampered by serious safe